Kevin Brennan - 16 Aug 2023 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
SVP, FINANCE AND ACCOUNTING
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
16 Aug 2023
Transactions value $
$0
Form type
4
Date filed
18 Aug 2023, 21:35
Previous filing
03 Apr 2023
Next filing
03 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +25K $0.00 25K 16 Aug 2023 Common Stock 25K $2.79 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date.